The IMPALA trial, a Phase 2/3 randomized, double-blind, placebo-controlled trial of molgramostim in 139 patients with aPAP, is the largest controlled clinical trial in this rare disease, and was conducted in 18 countries, including the U.S., Japan, and various European countries.

Results from the IMPALA trial give us confidence that molgramostim has the potential to address a significant unmet need in this rare disease —see results published in the New England Journal of Medicine in September 2020.

We are currently conducting IMPALA-2, a pivotal, Phase 3, 48-week, randomized, double-blind, placebo-controlled clinical trial of molgramostim in ~160 patients with aPAP. Additional information on IMPALA 2 can be found here.


Read more about aPAP and molgramostim.

Review articles & publications